MK 0354

Drug Profile

MK 0354

Alternative Names: MK-0354

Latest Information Update: 31 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; Merck & Co
  • Class Antihyperlipidaemics
  • Mechanism of Action G protein-coupled receptor agonists; GPR109A receptor agonists; GPR109B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atherosclerosis; Cardiovascular disorders; Lipid metabolism disorders

Most Recent Events

  • 25 Jan 2008 Discontinued - Preclinical for Undefined indication in USA (PO)
  • 29 Sep 2006 Discontinued - Phase-II for Atherosclerosis in USA (PO)
  • 29 Sep 2006 Discontinued - Phase-II for Cardiovascular disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top